Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Clearing the amyloid in Alzheimer's: progress towards earlier diagnosis and effective treatments - an update for clinicians.

    Access Status
    Fulltext not available
    Authors
    Asih, P.
    Chatterjee, P.
    Verdile, Giuseppe
    Gupta, V.
    Trengrove, R.
    Martins, R.
    Date
    2014
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Asih, P. and Chatterjee, P. and Verdile, G. and Gupta, V. and Trengrove, R. and Martins, R. 2014. Clearing the amyloid in Alzheimer's: progress towards earlier diagnosis and effective treatments - an update for clinicians. Neurodegenerative Disease Management. 4 (5): pp. 363-378.
    Source Title
    Neurodegenerative Disease Management
    DOI
    10.2217/NMT.14.29
    ISSN
    1758-2024
    URI
    http://hdl.handle.net/20.500.11937/44496
    Collection
    • Curtin Research Publications
    Abstract

    A beta (Aβ or β-amyloid) is a key molecule in Alzheimer's disease (AD) pathogenesis. According to the ‘amyloid hypothesis’, the gradual accumulation of Aβ triggers events which results in neuronal loss in regions of the brain involved with memory and learning. Diverse agents have been developed to reduce brain Aβ accumulation or to enhance its clearance. Some have progressed to human trials, however all have failed to improve cognition in patients. This has led researchers to question whether Aβ is really the problem. However, the trials have been targeting end stages of AD, by which stage extensive irreversible neuronal damage has already occurred. Intervention is required preclinically, therefore preclinical AD biomarkers are needed. In this regard, amyloid imaging and cerebrospinal fluid biomarkers are leading the way, with plasma biomarkers and eye tests also being investigated. This review covers the current state of knowledge of Aβ as an early diagnostic biomarker and as a therapeutic target in AD.

    Related items

    Showing items related by title, author, creator and subject.

    • Decreased platelet APP isoform ratios in autosomal dominant Alzheimer's disease: baseline data from a DIAN cohort subset
      Chatterjee, P.; Gupta, V.; Fagan, A.; Jasielec, M.; Xiong, C.; Sohrabi, H.; Dhaliwal, Satvinder; Taddei, K.; Bourgeat, P.; Brown, B.; Benzinger, T.; Bateman, R.; Morris, J.; Martins, R. (2015)
      Introduction: This study examines platelet amyloid precursor protein (APP) isoform ratios of 120KDa to 110KDa (APPr) between mutation carriers (MC) carrying a mutation for autosomal dominant Alzheimer's disease (ADAD) and ...
    • Associations between gonadotropins, testosterone and [beta] amyloid in men at risk of Alzheimer’s disease
      Verdile, Giuseppe; Laws, S.; Henley, D.; Ames, D.; Bush, A.; Ellis, K.; Faux, N.; Gupta, V.; Li, Q.; Masters, C.; Pike, K.; Rowe, C.; Szoeke, C.; Taddei, K.; Villemagne, V.; Martins, R. (2014)
      Testosterone and gonadotropins have been associated with cognitive decline in men and the modulation of β amyloid (Aβ) metabolism. The relatively few studies that have investigated whether changes in one or a combination ...
    • Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies
      Martins, R.; Villemagne, V.; Sohrabi, H.; Chatterjee, P.; Shah, T.; Verdile, Giuseppe; Fraser, P.; Taddei, K.; Gupta, V.; Rainey-Smith, S.; Hone, E.; Pedrini, S.; Lim, W.; Martins, I.; Frost, S.; Gupta, S.; O'Bryant, S.; Rembach, A.; Ames, D.; Ellis, K.; Fuller, S.; Brown, B.; Gardener, S.; Fernando, B.; Bharadwaj, Prashant; Burnham, S.; Laws, S.; Barron, A.; Goozee, K.; Wahjoepramono, E.; Asih, P.; Doecke, J.; Salvado, O.; Bush, A.; Rowe, C.; Gandy, S.; Masters, C. (2018)
      © 2018-IOS Press and the authors. All rights reserved. Worldwide there are over 46 million people living with dementia, and this number is expected to double every 20 years reaching about 131 million by 2050. The cost ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.